jeremy1

Jeremy Sivak, PhD holds the Glaucoma Research Chair at the Krembil Research Institute, University Health Network, and is Associate Professor at the department of Laboratory Medicine and Pathobiology in the University of Toronto.

Dr. Sivak completed his PhD in 2001 at Tufts University/New England Medical Center, followed by a postdoctoral fellowship at the University of Cambridge. He then joined Novartis in 2005 as a project lead where he led multidisciplinary ophthalmic drug discovery teams. Dr. Sivak returned to academics in 2010 to establish a research program that examines the mechanisms controlling retinal injury responses, and to design new treatment and drug delivery strategies. The success of this work is reflected in concurrent funding from federal, and non-profit granting agencies, industry collaborations, consistent publications in prominent journals, and broad lecturing internationally.

Selected Publications (Last 10 Years):

1. Vicic N, Guo X, Chan D, Flanagan JG, Sigal IA, Sivak JM. Evidence of an Annexin A4 mediated plasma membrane repair response to biomechanical strain associated with glaucoma pathogenesis. J Cell Physiol. 2022;237(9):3687-702. COVER IMAGE

2. Chan D, Won GJ, Read AT, Ethier CR, Thackaberry E, Crowell SR, Booler H, Bantseev V, Sivak JM. Application of an organotypic ocular perfusion model to assess intravitreal drug distribution in human and animal eyes. J R Soc Interface. 2022;19(186):20210734.

3. Mathew DJ, Livne-Bar I, Sivak JM. An inducible rodent glaucoma model that exhibits gradual sustained increase in intraocular pressure with distinct inner retina and optic nerve inflammation. Sci Rep. 2021;11(1):22880.

4. Alqawlaq S, Livne-Bar I, Williams D, D’Ercole J, Leung SW, Chan D, Tuccitto A, Datti A, Wrana JL, Corbett AH, Schmitt-Ulms G, Sivak JM. An endogenous PI3K interactome promoting astrocyte mediated neuroprotection identifies a novel association with RNA binding protein ZC3H14. J Biol Chem. 2020.

5. Kim C, Livne-Bar I, Gronert K, Sivak JM. Fair-Weather Friends: Evidence of Lipoxin Dysregulation in Neurodegeneration. Mol Nutr Food Res. 2020;64(4):e1801076.

6. Guo X, Jiang Q, Tuccitto A, Chan D, Alqawlaq S, Won GJ, Sivak JM. The AMPK-PGC-1alpha signaling axis regulates the astrocyte glutathione system to protect against oxidative and metabolic injury. Neurobiol Dis. 2018;113:59-69.

7. Livne-Bar I, Wei J, Liu HH, Alqawlaq S, Won GJ, Tuccitto A, Gronert K, Flanagan JG, Sivak JM. Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury. The Journal of Clinical Investigation. 2017;127(12):4403-14.

8. Livne-Bar I, Lam S, Chan D, Guo X, Askar I, Nahirnyj A, Flanagan JG, Sivak JM. Pharmacologic inhibition of reactive gliosis blocks TNF-alpha-mediated neuronal apoptosis. Cell Death & Disease. 2016;7(9):e2386.

9. Guo X, Dason ES, Zanon-Moreno V, Jiang Q, Nahirnyj A, Chan D, Flanagan JG, Sivak JM. PGC-1alpha signaling coordinates susceptibility to metabolic and oxidative injury in the inner retina. Am J Pathol. 2014;184(4):1017-29.

10. Sivak JM. The aging eye: common degenerative mechanisms between the Alzheimer’s brain and retinal disease. Invest Ophthalmol Vis Sci. 2013;54(1):871-80.

All of Dr. Jeremy Sivak’s publications here